aod9604 clinical trials safety | Peptra Labs AOD‑9604 Peptide for Fat Loss:

Although I could only find rat studies on PubMed, the peptide has generated excellent results in a Phase 2b clinical trial run by Metabolic Pharmaceuticals: The drug codenamed AOD9604 was taken orally once daily by 300 obese patients at five trial sites over a 12-week period

We say, YOU MATTER, because you are significant

Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs

Defined endpoint and review

Documentation is clear and easy to review. Reliable supplier with verified quality standards